Drugs of psychopharmacological revolution in clinical psychiatry

Psychiatric Services

Volumn 51, Issue 10, 2000, Pages 1254-1258

  Lieberman, J A ^a   Golden, R ^a   Stroup, S ^a   McEvoy, J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABILITAT; AMOXAPINE; ARIPRIPAZOLE; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; FLUOXETINE; FLUVOXAMINE MALEATE; HALOPERIDOL; ILOPERIDONE; MAPROTILINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTINDOLE; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; ZIPRASIDONE; ZOMARIL;

BONE MARROW TOXICITY; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESEARCH; HEART ARRHYTHMIA; HUMAN; MENTAL DISEASE; NOTE; PHASE 3 CLINICAL TRIAL; PSYCHOPHARMACOTHERAPY; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOPAMINE UPTAKE INHIBITORS; HISTORY OF MEDICINE, 20TH CENT.; HUMAN; PSYCHIATRY; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS; SUPPORT, U.S. GOV'T, P.H.S.; UNITED STATES;

EID: 0033770993     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.51.10.1254     Document Type: Note

References (30)

1. Clozapine treatment of outpatients with schizophrenia: Outcome and long-term response patterns
2. Psychopharmacologic treatment of schizophrenia
3. Cost of relapse in schizophrenia
4. Drug therapy: Schizophrenia
5. Predicting the 'revolving door' phenomenon among patients with schizophrenic, schizoaffective, and affective disorders
6. Service provision for people with schizophrenia: I. Clinical and economic perspective
7. Management of mental health and substance abuse services: State of the art and early results
8. New directions in research on involuntary outpatient commitment
9. Managing the care of schizophrenia: Lessons from a 4-year Massachusetts Medicaid study
10. Clozapine for the treatment-resistant schizophrenic
11. Mechanisms of action of atypical antipsychotic drugs: A critical analysis
12. Duration of a clozapine trial in neuroleptic-resistant schizophrenia
13. Emerging roles for novel antipsychotic medications in the treatment of schizophrenia
14. Clozapine-induced agranulocytosis: Incidence and risk factors in the United States
15. Efficacy and extrapyramidal effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials
16. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis
17. Antipsychotic-induced weight gain: A comprehensive research synthesis
18. Weight changes during clozapine treatment
19. Novel antipsychotics and new onset diabetes
20. Clozapine and associated diabetes mellitus
21. Psychiatric patients and treatments in 1997: Findings from the American Psychiatric Practice Research Network
22. Prescribing trends in psychotropic medication: Primary care, psychiatry, and medical specialties
23. Practice guideline for the treatment of patients with schizophrenia
24. The new antidepressants
25. Trazodone and other anti-depressants
26. The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment
27. The imipramine story
28. Monoamine oxidase inhibitors: An unfinished picaresque tale
29. Redefining the role of psychiatry in medicine